The cost of lung cancer in Alberta

被引:27
作者
Demeter, Sandor J. [1 ]
Jacobs, Philip [2 ]
Chniielowiec, ChesLer [3 ]
I-Ogus, Wayne [3 ]
Hailey, David [2 ]
Fassbender, Konrad [2 ]
McEwan, Alexander [3 ]
机构
[1] Univ Manitoba, Nucl Med Sect, Dept Radiol & Community Hlth Sci, Winnipeg, MB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
[3] Cross Canc Inst, Alberta Canc Board, Edmonton, AB T6G 1Z2, Canada
关键词
adininistrative medicine; health economics; lung neoplasm; oncolony;
D O I
10.1155/2007/847604
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
BACKGROUND: Lung cancer is the leading cause of cancer morbidity and mortality. In addition, lung cancer has a significant economic impact on society. OBJECTIVE: To present an economic analysis of the actual care costs of lung cancer which will allow comparison with, and verification of, cost estimates that were developed through modelling and opinion. METHODS: A chart review was conducted of incident cases (circa 1998) of Primary bronchogenic lung cancer. Cases were censored at two years from the date of diagnosis. Relevant clinical and health uitilization data were collected. Health Utilization data included hospital and institutional outpatient (ie, ambulatory clinic) costs. Cost estimates were derived for over 200 specific health services. The present analysis was performed from the economic perspective of the health care institution. RESULTS: A total of 13,389 health service events were captured with an estimated total cost of $8.4 million. Laboratory tests, diagnostic imaging and ambulatory visits constituted 86% of the Service events while patient admissions and therapy constituted 76% of the costs. The vast Majority of overall costs occured just before, or within, three months of diagnosis. The median nonsmall cell lung cancer and small cell lung cancer case costs were $10,928 (range $9,234 to $11,047) and $ 15,350 (range $13,033 to $21,436), respectively. CONCLUSION: The results agree with the literature that the majority of lung cancer case costs are realized around the date of diagnosis (ie, early phase). The present study illustrates canadian health care system lung cancer case costs based oil actual care received versus hypothetical care algorithms.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 20 条
[1]   The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer [J].
Coy, P ;
Schaafsma, J ;
Schofield, JA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (04) :1025-1033
[2]  
Demeter Sandor J, 2003, Can Respir J, V10, P435
[3]   Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer [J].
Earle, CC ;
Evans, WK .
BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) :815-820
[4]   Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer [J].
Esnaola, NF ;
Lazarides, SN ;
Mentzer, SJ ;
Kuntz, KM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :263-273
[5]  
Etzioni R, 2002, MED CARE, V40, P63
[6]  
Evans W K, 1995, Can J Oncol, V5, P408
[7]   The economics of lung cancer management in Canada [J].
Evans, WK ;
Will, BP ;
Berthelot, JM ;
Wolfson, MC .
LUNG CANCER, 1996, 14 (01) :19-29
[8]   Cost of combined modality interventions for stage III non-small-cell lung cancer [J].
Evans, WK ;
Will, P ;
Berthelot, JM ;
Earle, CC .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3038-3048
[9]  
EVANS WK, 1997, SEMIN ONCOL S7, V24
[10]   Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000 [J].
Fassbender, K ;
Fainsinger, R ;
Brenneis, C ;
Brown, P ;
Braun, T ;
Jacobs, P .
PALLIATIVE MEDICINE, 2005, 19 (07) :513-520